Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial
DA Reardon, AA Brandes, A Omuro… - JAMA …, 2020 - jamanetwork.com
Importance Clinical outcomes for glioblastoma remain poor. Treatment with immune
checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from
a randomized phase 3 clinical trial evaluating a programmed death-1 (PD-1) inhibitor
therapy for glioblastoma have not been reported. Objective To determine whether single-
agent PD-1 blockade with nivolumab improves survival in patients with recurrent
glioblastoma compared with bevacizumab. Design, Setting, and Participants In this open …
checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from
a randomized phase 3 clinical trial evaluating a programmed death-1 (PD-1) inhibitor
therapy for glioblastoma have not been reported. Objective To determine whether single-
agent PD-1 blockade with nivolumab improves survival in patients with recurrent
glioblastoma compared with bevacizumab. Design, Setting, and Participants In this open …